Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 J&J MedTech Resumes Varipulse PFA Cases in U.S.
OEM News

J&J MedTech Resumes Varipulse PFA Cases in U.S.

This comes after a voluntary pause last month due to reports of four reported neurovascular events in the evaluation.

The Varipulse pulsed field ablation (PFA) platform. Photo: Johnson & Johnson MedTech.

Johnson & Johnson MedTech announced that it has resumed the limited market release of the Varipulse pulsed field ablation (PFA) system in the U.S. after a comprehensive investigation.

This comes after a voluntary pause last month due to reports of four reported neurovascular events in the evaluation. J&J said that the devices were found to operate as intended, and will update the Instructions for Use (IFU) globally for the Varipulse catheter to include enhanced guidance.

J&J said the investigation into possible device-, procedure-, and patient-related factors also concluded no difference in performance of available Varipulse system configurations across the world.

“The investigation found the risk of neurovascular events may increase if a high number of ablations, the stacking of ablations, and/or ablations outside of the pulmonary veins are delivered,” the company told the press.

J&J said it’s communicating with clinicians using Varipulse to recommend they review and adhere to the updated IFU and share info with patients. The company is continuing to educate healthcare professionals with guidance around recommended practices aligned to its clinical studies.

The Varipulse PFA system earned U.S. Food and Drug Administration (FDA) approval to treat drug refractory, paroxysmal atrial fibrillation (AFib) in November 2024. It’s a treatment option for patients with atrial fibrillation (AFib) and remains available in all markets where it’s commercially launched.

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters